Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth R Plimack

Showing results (11-20 of 209) with videos related to

Pageof 21
Sort By:
European Urology|May 11, 2021
Systemic Therapy for Advanced Non-clear-Cell Renal Cell Carcinoma: Slow but Definite ProgressDaniel M Geynisman, Elizabeth R Plimack
Journal of Oncology Practice|May 11, 2017
Bending the Curve of Advanced Urothelial CarcinomaDaniel M Geynisman, Elizabeth R Plimack
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2016
Targeted Therapy for Metastatic Urothelial Cancer: A Work in ProgressElizabeth R Plimack, Daniel M Geynisman
Journal of the National Comprehensive Cancer Network : JNCCN|September 16, 2011
Selecting targeted therapies for patients with renal cell carcinomaElizabeth R Plimack, Gary R Hudes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2022
Platinum-Free Systemic Therapy in First-Line Metastatic Urothelial Carcinoma: Mirage or Oasis in the Platinum Desert?Elizabeth R Plimack, Matthew R Zibelman
Annals of Internal Medicine|October 27, 2015
Measuring the Efficacy and Value of Urothelial Cancer Urinary BiomarkersPhillip H Abbosh, Elizabeth R Plimack
Urologic Oncology|November 28, 2016
Emerging role of immunotherapy in urothelial carcinoma-Advanced diseaseMatthew Zibelman, Chethan Ramamurthy, Elizabeth R Plimack
European Urology|November 9, 2021
Placing Adjuvant Chemotherapy in the Evolving Paradigm of Perioperative Therapy for Bladder CancerBenjamin Miron, Laura Bukavina, Elizabeth R Plimack
The Journal of Urology|September 5, 2025
Editorial CommentGregory Hemenway, Elizabeth R Plimack, Daniel M Geynisman
European Urology|May 31, 2016
Second-generation Androgen Receptor-targeted Therapies in Nonmetastatic Castration-resistant Prostate Cancer: Effective Early Intervention or Intervening Too Early?Daniel M Geynisman, Elizabeth R Plimack, Matthew Zibelman
Pageof 21

Showing results (11-20 of 209) with videos related to

Sort By:
Pageof 21
European Urology|May 11, 2021
Systemic Therapy for Advanced Non-clear-Cell Renal Cell Carcinoma: Slow but Definite ProgressDaniel M Geynisman, Elizabeth R Plimack
Journal of Oncology Practice|May 11, 2017
Bending the Curve of Advanced Urothelial CarcinomaDaniel M Geynisman, Elizabeth R Plimack
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2016
Targeted Therapy for Metastatic Urothelial Cancer: A Work in ProgressElizabeth R Plimack, Daniel M Geynisman
Journal of the National Comprehensive Cancer Network : JNCCN|September 16, 2011
Selecting targeted therapies for patients with renal cell carcinomaElizabeth R Plimack, Gary R Hudes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2022
Platinum-Free Systemic Therapy in First-Line Metastatic Urothelial Carcinoma: Mirage or Oasis in the Platinum Desert?Elizabeth R Plimack, Matthew R Zibelman
Annals of Internal Medicine|October 27, 2015
Measuring the Efficacy and Value of Urothelial Cancer Urinary BiomarkersPhillip H Abbosh, Elizabeth R Plimack
Urologic Oncology|November 28, 2016
Emerging role of immunotherapy in urothelial carcinoma-Advanced diseaseMatthew Zibelman, Chethan Ramamurthy, Elizabeth R Plimack
European Urology|November 9, 2021
Placing Adjuvant Chemotherapy in the Evolving Paradigm of Perioperative Therapy for Bladder CancerBenjamin Miron, Laura Bukavina, Elizabeth R Plimack
The Journal of Urology|September 5, 2025
Editorial CommentGregory Hemenway, Elizabeth R Plimack, Daniel M Geynisman
European Urology|May 31, 2016
Second-generation Androgen Receptor-targeted Therapies in Nonmetastatic Castration-resistant Prostate Cancer: Effective Early Intervention or Intervening Too Early?Daniel M Geynisman, Elizabeth R Plimack, Matthew Zibelman
Pageof 21